...
首页> 外文期刊>Diabetologia >Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene
【24h】

Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene

机译:伴有KCNJ11基因中V59M突变的中度发育迟缓,早发性全身性癫痫和新生儿糖尿病综合征的患者,通过磺酰脲治疗可改善运动发育和良好的长期血糖控制

获取原文
获取原文并翻译 | 示例
           

摘要

Activating mutations in the KCNJ11 gene encoding the Kir6.2 subunit of the KATP channels in pancreatic beta cells are a common cause of neonatal diabetes. One-third of patients also have developmental delay, which probably results from mutated KATP channels in muscle, nerve and brain. Sulfonylureas, which bind to the sulfonylurea receptor 1 subunit of the KATP channel, can replace insulin injections in patients with KCNJ11 mutations. The aim of this study was to investigate the long-term outcome and impact on neurological features of sulfonylurea treatment.
机译:胰腺β细胞中编码KATP 通道Kir6.2亚基的KCNJ11基因的激活突变是新生儿糖尿病的常见原因。三分之一的患者也有发育迟缓,这可能是由于肌肉,神经和大脑中的KATP 通道突变造成的。与KATP 通道的磺酰脲受体1亚基结合的磺酰脲可以代替KCNJ11突变患者的胰岛素注射剂。这项研究的目的是调查磺脲类药物治疗的长期结果及其对神经功能的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号